More Company News

Redx Pharma

Interim H123 results for the six months ended 31 March
17 May 2023Read More

Redx Pharma

RXC007 preclinical data
11 May 2023Read More

Redx Pharma

Presentation at Keystone Symposia
03 May 2023Read More

Redx Pharma

Proposed business combination formally lapsed
03 Apr 2023Read More

Redx Pharma

Statement following Jounce announcement
27 Mar 2023Read More

Redx Pharma

Statement re: Jounce Therapeutics press release
15 Mar 2023Read More

Redx Pharma

RXC004 topline data from a Phase II monotherapy module
08 Mar 2023Read More

Redx Pharma

Recommended business combination with Jounce Therapeutics
23 Feb 2023Read More

Redx Pharma

Progress update on RXC007 clinical programme
09 Feb 2023Read More

Redx Pharma

FY22 Results
20 Dec 2022Read More

1 2 3 4 … 6
Return to Redx Pharma
© 2019-22 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).